Barclays’s AstraZeneca AZN Stock Holding History

Barclays’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-151,000	Closed	-$27.8M	–	5047
2025 Q4	$27.8M	Sell	151,000 -166,500	-52%	-$29.2M	0.01%	1064
2025 Q3	$48.7M	Sell	317,500 -45,000	-12%	-$6.81M	0.01%	782
2025 Q2	$50.7M	Buy	362,500 +45,000	+14%	+$6.31M	0.01%	704
2025 Q1	$46.7M	Buy	+317,500	New	+$45.9M	0.01%	679
2024 Q3	–	Sell	-45,450	Closed	-$7.09M	–	5290
2024 Q2	$7.09M	Buy	+45,450	New	+$6.84M	﹤0.01%	1342
2022 Q1	–	Sell	-1,550	Closed	-$181K	–	4944
2021 Q4	$181K	Hold	1,550	–	–	﹤0.01%	3598
2021 Q3	$186K	Hold	1,550	–	–	﹤0.01%	3654
2021 Q2	$186K	Hold	1,550	–	–	﹤0.01%	3587
2021 Q1	$154K	Sell	1,550 -4,700	-75%	-$472K	﹤0.01%	3818
2020 Q4	$625K	Hold	6,250	–	–	﹤0.01%	3101
2020 Q3	$685K	Sell	6,250 -4,300	-41%	-$478K	﹤0.01%	2990
2020 Q2	$1.12M	Sell	10,550 -4,750	-31%	-$491K	﹤0.01%	2660
2020 Q1	$1.37M	Sell	15,300 -20,200	-57%	-$1.9M	﹤0.01%	2641
2019 Q4	$3.54M	Buy	35,500 +1,900	+6%	+$179K	﹤0.01%	2383
2019 Q3	$3M	Sell	33,600 -82,850	-71%	-$7.18M	﹤0.01%	2387
2019 Q2	$9.61M	Sell	116,450 -120,800	-51%	-$9.47M	0.01%	1379
2019 Q1	$19.2M	Buy	237,250 +204,200	+618%	+$16.1M	0.01%	880
2018 Q4	$2.51M	Sell	33,050 -8,150	-20%	-$636K	﹤0.01%	2172
2018 Q3	$3.26M	Sell	41,200 -14,500	-26%	-$1.1M	﹤0.01%	2296
2018 Q2	$3.91M	Buy	55,700 +41,800	+301%	+$3.01M	﹤0.01%	1929
2018 Q1	$972K	Sell	13,900 -29,650	-68%	-$2.05M	﹤0.01%	3248
2017 Q4	$3.02M	Sell	43,550 -31,350	-42%	-$2.11M	﹤0.01%	2063
2017 Q3	$5.08M	Sell	74,900 -31,100	-29%	-$1.96M	0.01%	1518
2017 Q2	$7.23M	Buy	106,000 +12,450	+13%	+$813K	0.01%	1200
2017 Q1	$5.83M	Buy	93,550 +46,900	+101%	+$2.73M	0.01%	1225
2016 Q4	$2.55M	Sell	46,650 -60,700	-57%	-$3.45M	﹤0.01%	1925
2016 Q3	$7.05M	Buy	107,350 +80,500	+300%	+$5.26M	0.01%	1067
2016 Q2	$1.62M	Buy	26,850 +6,100	+29%	+$354K	﹤0.01%	2188
2016 Q1	$1.16M	Sell	20,750 -114,500	-85%	-$6.88M	﹤0.01%	2402
2015 Q4	$8.93M	Buy	135,250 +13,500	+11%	+$885K	0.01%	957
2015 Q3	$7.55M	Sell	121,750 -81,150	-40%	-$5.34M	0.01%	1101
2015 Q2	$12.8M	Buy	202,900 +45,700	+29%	+$3.13M	0.01%	886
2015 Q1	$10.7M	Sell	157,200 -1,451,000	-90%	-$101M	0.01%	1040
2014 Q4	$113M	Buy	1,608,200 +794,600	+98%	+$56.9M	0.11%	148
2014 Q3	$57.8M	Sell	813,600 -492,000	-38%	-$36M	0.06%	280
2014 Q2	$96.6M	Buy	1,305,600 +1,249,700	+2,236%	+$90.3M	0.1%	157
2014 Q1	$3.58M	Sell	55,900 -72,300	-56%	-$4.67M	﹤0.01%	1997
2013 Q4	$7.56M	Buy	128,200 +90,300	+238%	+$4.91M	0.01%	1477
2013 Q3	$1.93M	Sell	37,900 -200	-0.5%	-$10K	﹤0.01%	2622
2013 Q2	$1.8M	Buy	+38,100	New	+$1.94M	﹤0.01%	2657

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Barclays's AZN Position: Q1 2026 in Review

Barclays increased its AstraZeneca (AZN) stake by 300% in Q1 2026, buying an estimated $794M and bringing the position to 5,491,992 shares worth $1.08B. The position accounts for 0.26% of the portfolio, ranked #54.

Barclays first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Barclays held 5,491,992 shares of AstraZeneca worth $1.08B as of Q1 2026.
Barclays bought 4,119,190 AstraZeneca shares in Q1 2026, an estimated $794M.
AstraZeneca made up 0.26% of Barclays's portfolio in Q1 2026, its #54 holding.
Barclays first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.